Abstracts tagged "pregnancy"

Abstract Number: 1674 • ACR Convergence 2022
In Utero Exposure to Hydroxychloroquine Does Not Associate with Ocular Toxicity as Assessed by Optical Coherence Tomography Five Years After Birth
Peter Izmirly¹, Mala Masson², Michael Marmor³, Noel Zahr⁴, Nathalie Costedoat-Chalumeau⁵ and Jill Buyon¹, ¹NYU Grossman School of Medicine, New York, NY, ²NYU Langone Medical Center- Division of Rheumatology, New York, NY, ³Stanford University, Stanford, CA, ⁴Pitié-Salpêtrière Hospital, Paris, France, ⁵Inserm DR Paris 5, Paris, France
Background/Purpose: The preventive approach to congenital heart block with hydroxychloroquine (HCQ) [PATCH] study supported the efficacy of HCQ to reduce the recurrence rate of cardiac…
Abstract Number: 0958 • ACR Convergence 2022
Azathioprine Metabolite Levels and Outcomes During Pregnancies in Women with Rheumatic Disease
Stephen Balevic¹, Catherine Sims², Amanda Eudy³ and Megan Clowse², ¹Duke Clinical Research Institute, Durham, NC, ²Duke University, Durham, NC, ³Duke University, Raleigh, NC
Background/Purpose: Despite the wide use of AZA during pregnancy, there are no studies evaluating the impact of pregnancy on AZA metabolites 6-thioguanine nucleotide (6-TGN) and…
Abstract Number: 2022 • ACR Convergence 2022
Outcome of Pregnancy in Women with Primary Sjögren’s Syndrome Compared to the General Population: The French Multicenter Prospective GR2 Study
Gregoire Martin de Fremont¹, Nathalie Costedoat-Chalumeau², Rakiba Belkhir³, Gaelle Guettrot-Imbert⁴, Nathalie Morel⁴, Gaetane Nocturne⁵, Anna Molto⁶, Tiphaine Goulenok⁷, Elisabeth Diot⁸, Estibaliz Lazaro⁹, Laurent Perard¹⁰, Nicole Ferreira¹¹, Maelle Le Besnerais¹², Nicolas Limal⁷, Nihal Martis¹³, Noémie Abisror¹⁴, Odile Debouverie¹⁵, Christophe Richez¹⁶, Vincent Sobanski¹⁷, Francois Maurier¹⁸, Gaetan Sauvetre¹², Herve Levesque¹², Marie Agnes Timsit¹⁹, Nathalie Tieule¹³, Pauline Orquevaux²⁰, GEFA Collaborative group²¹, Matthieu Mahevas²², Celine Lartigau Roussin²³, Elodie Chauvet²⁴, Emilie Berthoux²⁵, Francoise Sarrot Reynauld²⁶, Loic Raffray²⁷, Marion Couderc²⁸, Nicolas Martin Silva²⁹, Noemie Jourde Chiche³⁰, Nicolas Belhomme³¹, Thierry Thomas³², Vincent Poindron³³, Viviane Queyrel¹³, Juliette Delforge³⁴, Camille Le Ray³⁵, Emmanuelle Pannier³⁵, Xavier Mariette³⁶, Veronique Le Guern⁴ and Raphaèle Seror³⁷, ¹Rheumatology department, Kremlin Bicêtre hospital, APHP, Paris, France, ²Inserm DR Paris 5, Paris, France, ³Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, ⁴Hôpital Cochin, Paris, France, ⁵APHP, Le Kremlin Bicêtre, France, ⁶Rheumatology Department, Cochin Hospital, APHP, Paris, France, ⁷APHP, Paris, France, ⁸CHU Tours, Tours, France, ⁹Bordeaux Hospital University, Bordeaux, France, ¹⁰CHU Lyon, Lyon, France, ¹¹department of Internal Medecine, CHU de Tours, Tours, France, ¹²CHU Rouen, Rouen, France, ¹³CHU Nice, Nice, France, ¹⁴Hopital Saint Antoine, Paris, France, ¹⁵CHU Poitiers, Poitiers, France, ¹⁶Université de Bordeaux, Bordeaux, France, ¹⁷Université de Lille, Lille, France, ¹⁸Hôpitaux privés de Metz, Metz, France, ¹⁹CHU Brest, Brest, France, ²⁰CHU Reims, Reims, France, ²¹Saint Joseph Hospital, Marseille, France, ²²CHU Mondor, Creteil, France, ²³CH La Réunion, CH la Réunion, France, ²⁴CH Cabestany, Cabestany, France, ²⁵CH Saint Joseph Saint Luc, Lyon, France, ²⁶CHU Grenoble, CHU Grenoble, France, ²⁷CH St Denis Reunion, Saint Denis Reunion, France, ²⁸University Hospital, Clermont-Ferrand, France, ²⁹CHU Caen, Caen, France, ³⁰APHM, Marseille, France, ³¹CHU Rennes, Rennes, France, ³²CHU Saint Etienne, Saint Etienne, France, ³³Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ³⁴Jean Verfier, Bobigny, France, ³⁵Port Royal, Paris, France, ³⁶Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ³⁷University Hospital Paris-Saclay, Le Kremlin Bicêtre, France
Background/Purpose: In the context of primary Sjögren's syndrome (pSS), only a few retrospective studies using heterogeneous methods have investigated the risk of adverse pregnancy outcomes…
Abstract Number: 1711 • ACR Convergence 2021
Increasing Preeclampsia Knowledge in SLE with a Specific Educational Tool: Preliminary Results
Joo Young (Esther) Lee¹, Arielle Mendel², Isabelle Malhamé², Sasha Bernatsky¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Pregnant women with systemic lupus erythematosus (SLE) are at high risk of preeclampsia, leading to substantial maternal and fetal morbidity. Aspirin reduces preeclampsia risk…
Abstract Number: 1712 • ACR Convergence 2021
Adverse Outcomes and Rehospitalization After Delivery Among Women with Systemic Lupus Erythematosus or Rheumatoid Arthritis and Their Infants
Julianna Sabo¹, Namrata Singh², Deborah Crane¹, David Doody³, Melissa Schiff⁴ and Beth Mueller⁵, ¹University of Washington, Seattle, WA, ²University of Washington, Bellevue, WA, ³Fred Hutchinson Cancer Research Center, Seattle, WA, ⁴University of Washington, University of New Mexico, Seattle, WA, ⁵Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
Background/Purpose: Women with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) have greater risk of adverse obstetric and birth outcomes than women without these conditions.…
Abstract Number: 1713 • ACR Convergence 2021
Risk of Serious Infections in Offspring Exposed in Utero to Ustekinumab or Vedolizumab
Jonah Gorodensky¹, Sasha Bernatsky¹, Waqqas Afif¹, Yvan St-Pierre², Kristian Filion¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Ustekinumab, an IL-12/23 inhibitor, is indicated in adult patients with inflammatory bowel disease (IBD), psoriasis (PsO), and psoriatic arthritis (PsA) and vedolizumab, an α4β7…
Abstract Number: 1716 • ACR Convergence 2021
Teratogenic Medication Use Associated with Favorable Odds of Contraception Counseling in a Cohort of Women with Systemic Lupus Erythematosus at a Large Tertiary Academic Medical Center
Shruti Chandramouli¹, Carolina Alvarez², R. Gina Silverstein³ and Saira Sheikh⁴, ¹Department of Internal Medicine, Division of Rheumatology, Allergy & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Department of Obstetrics & Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC
Background/Purpose: Systemic lupus erythematosus (SLE) primarily affects women of childbearing age, who have an increased risk of pregnancy complications such as preterm labor and preeclampsia,…
Abstract Number: 0023 • ACR Convergence 2021
Investigating Temporal Changes in Pregnancy Among Women with Rheumatoid Arthritis and Healthy Women Using Co-expression Network Analysis
Matthew Wright¹, Dana Goin², Mette Smed³, J Lee Nelson⁴, Nicholas Jewell⁵, Jorn Olsen⁶, Merete Hetland⁷, Vibeke Zoffmann³ and Damini Jawaheer⁸, ¹UCSF Benioff Children's Hospital Oakland, Oakland, CA, ²University of California San Francisco, San Francisco, CA, ³Juliane Marie Center, Rigshospitalet, Copenhagen, Denmark, ⁴Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, ⁵University of California Berkeley, Berkeley, CA, ⁶Aarhus University Hospital, Aarhus, Denmark, ⁷DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁸UCSF Benioff Children's Hospital Oakland / University of California San Francisco, Oakland, CA
Background/Purpose: Rheumatoid arthritis (RA), while still an incurable disease, can often improve naturally during pregnancy. The specific mechanism(s) underlying this pregnancy-induced improvement, however, are not…
Abstract Number: 1717 • ACR Convergence 2021
One Year After the Publication of the American College of Rheumatology (ACR) Guidelines for Management of Reproductive Health in Rheumatic Diseases, Has Anything Changed? An Analysis of Rheumatology Practice at a Tertiary Care Medical Center
Yixuan Zhou¹ and Sobia Hassan², ¹Rush University Medical Center, Chicago, IL, ²RUSH University, Chicago, IL
Background/Purpose: Successful pregnancies in patients with rheumatic disease are possible when they are well-monitored, adequately treated, and planned during periods of disease quiescence. Previously, a…
Abstract Number: 0070 • ACR Convergence 2021
Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Zeynep Belce Erton¹, Ecem Sevim², Guilherme Ramires de Jesus³, Ricard Cervera⁴, Lanlan Ji⁵, Vittorio Pengo⁶, Amaia Ugarte⁷, Danieli Andrade⁸, Laura Andreoli⁹, Tatsuya Atsumi¹⁰, Paul R Fortin¹¹, Maria Gerosa¹², Yu Zuo¹³, Michelle Petri¹⁴, Savino Sciascia¹⁵, Maria Tektonidou¹⁶, Maria Angeles Aguirre¹⁷, D. Ware Branch¹⁸, Doruk Erkan¹ and on Behalf of APS ACTION¹, ¹Hospital for Special Surgery, New York, NY, ²Montefiore Medical Center - Wakefield Campus, Bronx, NY, ³Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁴Hospital Clinic Barcelona, Barcelona, Spain, ⁵Peking University First Hospital, Beijing, China (People's Republic), ⁶Padova University Hospital, Padova, Italy, ⁷Hospital Universitario Cruces, Barakaldo, Spain, ⁸Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁹University of Brescia, Brescia, Italy, ¹⁰Hokkaido University, Sapporo, Japan, ¹¹CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹²University of Milan, Milan, Italy, ¹³University of Michigan, Ann Arbor, MI, ¹⁴Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁵University of Turin, Turin, Italy, ¹⁶FORZAFORTE HELLAS LTD, Athens, Greece, ¹⁷IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ¹⁸University of Utah, Salt Lake City, UT
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL) positive patients with or…
Abstract Number: 1719 • ACR Convergence 2021
Pandemic-Associated Complications in Pregnant Women with Rheumatic Diseases
Diana Johnson, Hiral Dave, Yunjun Luo and Christina Chambers, University of California San Diego, La Jolla, CA
Background/Purpose: Pregnant women with rheumatic diseases may have been particularly vulnerable to the various consequences of the current pandemic, whether or not they were infected…
Abstract Number: 0079 • ACR Convergence 2021
Association Between Preconception Complement Levels and Use of Hydroxychloroquine with Pregnancy Outcome in Patients with Primary Antiphospholipid Syndrome and Carriers of Antiphospholipid Antibodies: An International Multicenter Study
Daniele Lini¹, Cecilia Nalli², Laura Andreoli³, Francesca Crisafulli¹, Micaela Fredi¹, Maria Grazia Lazzaroni¹, Viktoria Bitsadze⁴, Antonia Calligaro⁵, Valentina Canti⁶, Roberto Caporali⁷, Francesco Carubbi⁸, Cecilia Chighizola⁹, Paola Conigliaro¹⁰, Fabrizio Conti¹¹, Caterina De Carolis¹², Teresa Del Ross⁵, Maria Favaro⁵, Maria Gerosa⁹, Annamaria Iuliano¹³, Jamilya Khizroeva⁴, Alexander Makatsariya⁴, Pier Luigi Meroni¹⁴, Marta Mosca¹⁵, Melissa Padovan¹⁶, Roberto Perricone¹⁰, Patrizia Rovere Querini⁶, Gian Domenico Sebastiani¹³, Chiara Tani¹⁷, Marta Tonello¹⁸, Simona Truglia¹¹, Dina Zucchi¹⁵, Franco Franceschini¹ and Angela Tincani¹⁹, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ³University of Brescia, Brescia, Italy, ⁴Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia, ⁵Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy, ⁶Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁷Policlinico S. Matteo University, Pavia, Italy, ⁸Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L'Aquila, L'Aquila, Italy, ⁹University of Milan, Milan, Italy, ¹⁰Rheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy, ¹¹Lupus Clinic, Reumatologia, Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Rome, Italy, ¹²Polymedical Center for Prevention of Recurrent Spontaneous Abortion, Rome, Italy, ¹³Rheumatology Unit, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy, ¹⁴Division of Rheumatology, ASST.G Pini, Department of Clinical Sciences and Community Health, University of Milan and Istituto Auxologico Italiano, Milan, Italy, ¹⁵Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹⁶Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Italy, ¹⁷Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹⁸BSC, Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy, ¹⁹ASST Spedali Civili-University of Brescia, Gussago, Italy
Background/Purpose: APS is a rare autoimmune disease characterized by thrombotic events and/or pregnancy morbidities in the presence of confirmed positivity for aPL. Complement was demonstrated…
Abstract Number: 1722 • ACR Convergence 2021
Risk of Pre-eclampsia and Impact of Disease Activity and Anti-rheumatic Treatment in Women with Rheumatoid Arthritis, Axial Spondylarthritis, and Psoriatic Arthritis – A Collaborative Matched Cohort Study from Sweden and Denmark
Anne Emilie Secher¹, Karin Hellgren², Bente Glintborg³, Ane Rom⁴, Merete Hetland⁵ and Fredrik Granath², ¹COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Frederiksberg, Denmark, ²Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ³COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Glostrup, Denmark, ⁴The Juliane Marie Centre, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Denmark, ⁵DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Pre-eclampsia is a pregnancy-related syndrome with potentially fatal outcomes. In RA, high disease activity has been associated to adverse pregnancy outcomes such as preterm…
Abstract Number: 0236 • ACR Convergence 2021
Maternal Attachment, Anxiety and Depressive Symptoms in Pregnant Women with Rheumatic Diseases
Luis Gerardo Espinosa-Banuelos¹, Diana Carolina Rubio Torres², Maria Corral², Cassandra Skinner Taylor², Lorena Perez-Barbosa², Luz Fernanda Gutierrez Leal², Abraham Yair Lujano-Negrete³, Jesus Cardenas-de La Garza² and Dionicio Galarza-Delgado², ¹Faculty of Medicine and University Hospital Dr. Jose Eleuterio Gonzalez, UANL, Monterrey, Mexico, ²Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico, ³Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico
Background/Purpose: Untreated perinatal anxiety symptomatology can be related to symptoms of anxiety and depression during the postpartum. The psychological bond created by the mother between…
Abstract Number: 1723 • ACR Convergence 2021
Factors Associated with Postpartum Flare in Women with Lupus
Anitha Ramu¹, Maedeh Veyseh¹, Brianna Lally², Shudan Wang³ and Anna Broder⁴, ¹Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ⁴Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Several prior studies have assessed disease activity in the setting of pregnancy and have shown that certain factors such as thrombocytopenia, systemic lupus erythematosus…

« Previous Page
1
…
8
9
10
11
12
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.